Ivan Inigo

Discovery of <i>N</i>-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Louis J. Lombardo, Francis Y. Lee, Ping Chen et al. · Journal of Medicinal Chemistry · 2004 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Rikke Holmgaard, David Schaer, Yanxia Li et al. · Journal for ImmunoTherapy of Cancer · 2018 · 369 citations · Full text

Life Sciences, Immunology, Oncology +17

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Feng Luo, Zheng Yang, Amy Camuso et al. · Clinical Cancer Research · 2006 · 149 citations

Medicine, Pharmacokinetics, Pharmacology +13

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

Feng Luo, Zheng Yang, Huijing Dong et al. · Cancer Chemotherapy and Pharmacology · 2005 · 87 citations

Medicine, Oncology, Pharmacokinetics +11

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

Helen Kotanides, Yiwen Li, Maria Malabunga et al. · Cancer Immunology Research · 2020 · 68 citations

Life Sciences, Immunology, Oncology +17